Otsuka Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
96
About the Report
About the Report
Summary
Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mate protein jelly, metro mint, the calcium, oronine and new sararin, among others. Its pharmaceutical products are used in the areas of central nervous system, cardiovascular, circulatory disease, infectious diseases, kidney, digestive disease, ophthalmology and dermatology. The company operates in the US, Japan, Belgium, Australia, the UK, Denmark, and others. OPC is headquartered in Tokyo, Japan.
Otsuka Pharmaceutical Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Otsuka Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Partnerships 16
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 16
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 33
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 34
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 35
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 37
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39
Otsuka Pharma Amends Co-Development Agreement With UCB 41
Licensing Agreements 43
Otsuka Pharma Enters into Licensing Agreement with X-Chem 43
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 44
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 45
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 46
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 47
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 48
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 50
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 51
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 52
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 53
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 54
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 55
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 56
Otsuka Pharma Enters Into Licensing Agreement With Eisai 58
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 59
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 60
Equity Offering 61
Taiko Pharma to Raise Funds through Private Placement of Shares 61
Avanir Pharma Raises USD230 Million in Public Offering of Shares 62
Ribomic Raises USD26 Million in IPO of Shares 64
GlycoNex Announces Private Placement Of Shares For USD 9.2 Million 66
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 150 Million 67
Avanir Pharma Increases Size Of Private Placement Of Shares For USD 80 Million 68
Astex Pharma Files Registration Statement For Public Offering Of Securities For USD 200 Million 69
Asset Transactions 71
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 71
Acquisition 73
Otsuka Pharma Acquires Visterra for USD430 Million 73
Otsuka Pharma to Acquire Neurovance 74
Otsuka Acquires Avanir Pharma for USD3.5 Billion 75
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 77
Otsuka Pharma Completes Acquisition Of Astex Pharma For USD 886 Million 78
Gimv Sells Stake In Astex Therapeutics 80
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 81
Otsuka Pharmaceutical Co Ltd-Key Competitors 82
Otsuka Pharmaceutical Co Ltd-Key Employees 83
Otsuka Pharmaceutical Co Ltd-Locations And Subsidiaries 84
Head Office 84
Other Locations & Subsidiaries 84
Joint Venture 90
Recent Developments 91
Product News 91
Aug 21, 2018: TrialAssure partners with Otsuka Pharmaceutical to provide clinical trial disclosure reporting system for global pipeline 91
Apr 25, 2018: Proteus Digital Health Announces Digital Medicines Pipeline Development and Expansion into Oncology 92
Other Significant Developments 93
May 09, 2018: Otsuka Pharmaceutical Development & Commercialization Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool 93
Feb 28, 2018: Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care 94
Dec 13, 2017: Otsuka Pharmaceutical Unveils It's Completely New Website 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
List of Figure
List of Figures
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Otsuka Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 16
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 33
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 34
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 35
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 37
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39
Otsuka Pharma Amends Co-Development Agreement With UCB 41
Otsuka Pharma Enters into Licensing Agreement with X-Chem 43
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 44
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 45
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 46
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 47
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 48
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 50
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 51
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 52
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 53
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 54
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 55
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 56
Otsuka Pharma Enters Into Licensing Agreement With Eisai 58
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 59
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 60
Taiko Pharma to Raise Funds through Private Placement of Shares 61
Avanir Pharma Raises USD230 Million in Public Offering of Shares 62
Ribomic Raises USD26 Million in IPO of Shares 64
GlycoNex Announces Private Placement Of Shares For USD 9.2 Million 66
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 150 Million 67
Avanir Pharma Increases Size Of Private Placement Of Shares For USD 80 Million 68
Astex Pharma Files Registration Statement For Public Offering Of Securities For USD 200 Million 69
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 71
Otsuka Pharma Acquires Visterra for USD430 Million 73
Otsuka Pharma to Acquire Neurovance 74
Otsuka Acquires Avanir Pharma for USD3.5 Billion 75
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 77
Otsuka Pharma Completes Acquisition Of Astex Pharma For USD 886 Million 78
Gimv Sells Stake In Astex Therapeutics 80
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 81
Otsuka Pharmaceutical Co Ltd, Key Competitors 82
Otsuka Pharmaceutical Co Ltd, Key Employees 83
Otsuka Pharmaceutical Co Ltd, Other Locations 84
Otsuka Pharmaceutical Co Ltd, Subsidiaries 84
Otsuka Pharmaceutical Co Ltd, Joint Venture 90
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.